Main Menu

Description of Technology:

CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface.

Summary:

The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.

Summary:

The NCI is currently seeking research co-development partners for this first-in-kind computational method that is predictive of therapeutic response based on clonal SC gene expression of tumors.

Description of Technology:

Tailoring the best treatments to cancer patients remains a highly important endeavor in the oncology field. However, personalized treatment courses are challenging to determine, and technologies or methods that can successfully be employed for precision oncology are lacking.

Summary:

The NCI seeks licensees for this technology who are interested in using NCINM, including their implementation within existing commercial solutions for patient dose monitoring. Applications of the NCINM program include computation of absorbed doses for use in radiation epidemiologic studies and patient dose monitoring in nuclear medicine.

Summary:

The Surgery Branch seeks licensees for research use of TCRs targeting EGFR L858R mutation. 

Summary:

Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.

Summary:

The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.

Summary:

The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.

Summary:

The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.

Description of Technology:

The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. Recent studies using fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (RNAseq) to elucidate tissue composition and cell-cell interactions in the TME led to improved biomarkers of patient response and new treatment opportunities.